Sue Hager is an advisory partner on a16z’s Bio + Health team. Previously, she was chief investor relations and communications officer at Section 32 and led communications, health policy and advocacy at EQRx and Foundation Medicine, where she helped secure broad Medicare coverage for comprehensive genomic profiling in oncology. Earlier, she held similar roles at Bayer Healthcare, Myriant, Targanta and Coley Pharmaceutical. She serves on the boards of MassBio and the Emily Whitehead Foundation.
Sue Hager is an advisory partner on a16z’s Bio + Health team. Previously, she was chief investor relations and communications officer at Section 32 and led communications, health policy and advocacy at EQRx and Foundation Medicine, where she helped secure broad Medicare coverage for comprehensive genomic profiling in oncology. Earlier, she held similar roles at Bayer Healthcare, Myriant, Targanta and Coley Pharmaceutical. She serves on the boards of MassBio and the Emily Whitehead Foundation.
Career
Sue Hager holds an MBA; B.S. in Biology with honors from Northeastern University.
Advisory Partner, Bio + Health at Andreessen Horowitz (a16z) until Present